Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer

por You, Shuhui, Gong, Chengcheng, Li, Yi, Xie, Yizhao, Li, Yumeng, Zhao, Yannan, Wang, Biyun
Publicado 2023

Pretreatment (18)F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer

por Ma, Guang, You, Shuhui, Xie, Yizhao, Gu, Bingxin, Liu, Cheng, Hu, Xichun, Song, Shaoli, wang, Biyun, Yang, Zhongyi
Publicado 2023

Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by (18)F-FES PET

por Xie, Yizhao, Du, Xinyue, Zhao, Yannan, Gong, Chengcheng, Hu, Shihui, You, Shuhui, Song, Shaoli, Hu, Xichun, Yang, Zhongyi, Wang, Biyun
Publicado 2022